Literature DB >> 11583864

Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.

A Al-Ahmad1, W M Rand, G Manjunath, M A Konstam, D N Salem, A S Levey, M J Sarnak.   

Abstract

OBJECTIVES: We sought to evaluate the relationship between the level of kidney function, level of hematocrit and their interaction on all-cause mortality in patients with left ventricular (LV) dysfunction.
BACKGROUND: Anemia and reduced kidney function occur frequently in patients with heart failure. The level of hematocrit and its relationship with renal function have not been evaluated as risk factors for mortality in patients with LV dysfunction.
METHODS: We retrospectively examined the Studies Of LV Dysfunction (SOLVD) database. Glomerular filtration rate (GFR) was predicted using a recently validated formula. Kaplan-Meier survival analyses were used to compare survival times between groups stratified by level of kidney function (predicted GFR) and hematocrit. Cox proportional-hazards regression was used to explore the relationship of survival time to level of kidney function, hematocrit and their interaction.
RESULTS: Lower GFR and hematocrit were associated with a higher prevalence of traditional cardiovascular risk factors. In univariate analysis, reduced kidney function and lower hematocrit, in men and in women, were risk factors for all-cause mortality (p < 0.001 for both). After adjustment for other factors significant in univariate analysis, a 10 ml/min/1.73 m(2) lower GFR and a 1% lower hematocrit were associated with a 1.064 (95% CI: 1.033, 1.096) and 1.027 (95% CI: 1.015, 1.038) higher risk for mortality, respectively. At lower GFR and lower hematocrit, the risk was higher (p = 0.022 for the interaction) than that predicted by both factors independently.
CONCLUSIONS: Decreased kidney function and anemia are risk factors for all-cause mortality in patients with LV dysfunction, especially when both are present. These relationships need to be confirmed in additional studies.

Entities:  

Mesh:

Year:  2001        PMID: 11583864     DOI: 10.1016/s0735-1097(01)01470-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  118 in total

1.  Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes?

Authors:  N Cromie; C Lee; A D Struthers
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

2.  Anaemia and heart failure.

Authors:  A J S Coats
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

3.  Cardiorenal Resynchronization Therapy: Strengthening the Heart and Kidneys.

Authors:  Edmond K Obeng-Gyimah; Rajat Deo
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-25       Impact factor: 8.237

4.  The natural history of preclinical diastolic dysfunction: a population-based study.

Authors:  Mark W Vogel; Joshua P Slusser; David O Hodge; Horng H Chen
Journal:  Circ Heart Fail       Date:  2012-01-25       Impact factor: 8.790

5.  Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device.

Authors:  Michael E Nassif; Jayendrakumar S Patel; Jerrica E Shuster; David S Raymer; Ronald Jackups; Eric Novak; Brian F Gage; Sunil Prasad; Scott C Silvestry; Gregory A Ewald; Shane J LaRue
Journal:  JACC Heart Fail       Date:  2015-02       Impact factor: 12.035

6.  Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring--further insights from SOLVD.

Authors:  Simon de Denus; Jean-Claude Tardif; Michel White; Martial G Bourassa; Normand Racine; Sylvie Levesque; Anique Ducharme
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

7.  Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.

Authors:  M R Silver; R Geronemus; M Krause; C Y Chen; R Kewalramani; C Stehman-Breen
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

8.  A prognostic index for risk stratification for acute heart failure and death in subjects with ischemic cardiomyopathy and cardiac defibrillator.

Authors:  Lanfranco Antonini; Cristina Mollica; Antonio Auriti; Christian Pristipino; Vincenzo Pasceri; Francesca Leone; Salvatore Greco
Journal:  Heart Vessels       Date:  2015-05       Impact factor: 2.037

9.  Erythropoietin in cardiorenal anemia syndrome.

Authors:  Emir Fazlibegović; Mustafa Hadziomerović; Slavica Corić; Emil Babić; Fadila Fazlibegović
Journal:  Bosn J Basic Med Sci       Date:  2006-11       Impact factor: 3.363

10.  Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.

Authors:  Pupalan Iyngkaran; Merlin Thomas; William Majoni; Nagesh S Anavekar; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2012-10-31       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.